In the process of observation after their anti-BCMA CAR-T cell therapy, the examination to R/R MM patients with extramedullary disease should be comprehensive, rather than just observing the changes of M protein levels. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.